MarginsXMarginsX
Home › Markets › Health Care › AMGN

Amgen Inc. (AMGN)

AMGN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$462.32
-0.72% on the day
Market cap
$250.1B
Mega cap
Revenue · 2025
$36.8B
+10.0% on 2024
Net income · 2025
$7.7B
21.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/0000318154-26-000010-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerAMGN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year1983
SEC CIK0000318154
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$36.8B
Net income$7.7B
Operating income$9.1B
Net margin21.0%
Operating margin24.7%
Revenue growth+10.0%
Cash$9.1B
Total assets$90.6B
P/E (computed)32.4×
P/S (computed)6.8×

Warning signs

Cash runway
Cash-flow positive
$13.2B cash at September 30, 2026
Share count, 1 year
+0.5%
2025-10-30 to 2026-10-29 · +1.1% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$29.3M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$13.2B cash; operating cash flow $3.0B a quarter.Report 2026-09-30
Shares outstanding540,911,490 (2026-10-29); 538,480,671 a year earlier; 535,178,027 three years earlier.Cover page 2026-10-29
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-02-13
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
Delisting25-NSE filed25-NSE 2026-02-24
AuditorErnst & Young LLP, Los Angeles, California, United StatesPCAOB Form AP 2026-03-02
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $29.3M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$10.4B$3.9B$4.2B$13.2B$54.0B$38.9B10-Q 2026-11-04
Q2 2026
2026-06-30
$10.1B$2.4B$4.0B$14.0B$57.3B$38.1B10-Q 2026-08-05
Q1 2026
2026-03-31
$8.6B$1.8B$2.2B$12.0B$57.3B$37.2B10-Q 2026-05-01
Q4 2025
2025-12-31
$9.9B$1.3B$1.6B$9.1B$54.6B$36.8B10-K 2026-02-13
Q3 2025
2025-09-30
$9.6B$3.2B$4.7B$9.4B$54.6B$36.0B10-Q 2026-11-04
Q2 2025
2025-06-30
$9.2B$1.4B$2.3B$8.0B$56.2B$34.9B10-Q 2026-08-05
Q1 2025
2025-03-31
$8.1B$1.7B$1.4B$8.8B$57.4B$34.1B10-Q 2026-05-01
Q4 2024
2024-12-31
$9.1B$627.0M$4.8B$12.0B$60.1B$33.4B10-K 2026-02-13

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B22026-02-19
Latest annual report10-K2026-02-13
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-03
Latest proxyDEFA14A2026-04-21

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+1.1%
1 month+12.8%
3 months+11.4%
Year to date+42.3%
1 year+38.6%
From 52-week high-2.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
GILDGilead Sciences Inc.$167.58-0.30%$207.9B
MRNAModerna Inc.$215.27-3.63%$87.1B
ARGXargenx SE$950.95-0.95%$59.0B
BIIBBiogen Inc.$251.65-0.69%$37.2B
RVMDRevolution Medicines Inc.$166.87-3.15%$36.1B
BNTXBioNTech SE American Depositary Share$85.26-0.40%$21.4B
NBIXNeurocrine Biosciences Inc.$165.31-1.25%$16.7B
EXELExelixis Inc.$67.10-2.75%$16.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier